ReviewInternational journal of molecular sciences2023
Hepatocellular Carcinoma: Past and Present Challenges and Progress in Molecular Classification and Precision Oncology.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- The potential of soluble programmed cell death-ligand 1 and soluble programmed cell death 1 as diagnostic and prognostic biomarkers for hepatocellular carcinoma: a meta-analysis.Irish journal of medical science · 2025Pooled it
- VMAT-based lattice radiotherapy for advanced bulky hepatocellular carcinoma within multimodality treatment: a consecutive feasibility series.Clinical and translational radiation oncology · 2026Article
- Nanostructured lipid carriers as co-delivery systems for cancer therapy: Prospects and challenges.International journal of pharmaceutics: X · 2026Review
- Functional Interpretation of Recurrent Genetic Variants in Hepatocellular Carcinoma: Molecular Consequences and Clinical Relevance.Human mutation · 2026Review
- DeepPNCC: reconstructing pseudo-spatial cell-cell interaction landscapes from single-cell data to decipher breast cancer pathogenesis.Journal of translational medicine · 2025Article
- Article
- Explainable artificial intelligence and ensemble learning for hepatocellular carcinoma classification: State of the art, performance, and clinical implications.World journal of hepatology · 2025Review
- RBM17 promotes hepatocellular carcinoma progression by regulating lipid metabolism and immune microenvironment: implications for therapeutic targeting.Cell death discovery · 2025Article
- Exosomes in Hepatocellular Carcinoma: A Comprehensive Review of Current Research and Future Directions.Journal of cellular and molecular medicine · 2025Review
- Evaluation of the efficacy of laparoscopic hepatolobectomy for primary liver cancer with early combined enteral and parenteral nutritional support.Discover oncology · 2025Article
- Metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma: Challenges in clinical practice.Clinical and experimental hepatology · 2025Review
- Mechanism of atorvastatin in treating hepatocellular carcinoma: a study based on network pharmacology, molecular docking, and bioinformatics analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Anti-tumor efficacy and safety of AEV01 in preclinical glioblastoma and hepatocellular carcinoma models.Scientific reports · 2025Article
- Identification and validation of PANoptosis-related LncRNAs prognosis system in hepatocellular carcinoma.Scientific reports · 2025Article
- A novel ubiquitination-related gene signature for overall survival prediction in patients with liver hepatocellular carcinoma.Discover oncology · 2025Article
- Evolution of Clinical Trials of Systemic Therapies for Hepatocellular Carcinoma Between 2005 and 2024: Based on ClinicalTrials.gov.Gastro hep advances · 2025Review
- Solute carrier family 2 member 2 (glucose transporter 2): a common factor of hepatocyte and hepatocellular carcinoma differentiation.PloS one · 2025Article
- Heparan sulfate chains in hepatocellular carcinoma.Gastroenterology report · 2025Review
- Article
- Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common solid tumor malignancies in the world and represents roughly 90% of all primary malignancies of the liver. The most common risk factors for HCC include hepatitis B virus, hepatitis C virus, alcohol, and increasingly, fatty liver. Most HCC is diagnosed at advanced stages, excluding the possibility of curative resection, which leaves systemic therapy as the only treatment option. However, given the extreme mutational diversity and heterogenous nature of HCC, efforts to develop new targeted systemic therapies were largely unsuccessful until recently. HCC pathogenesis is thought to be a multistage process driven by a wide array of nonmutually exclusive driver mutations accompanied by many passenger mutations, with the average tumor possessing approximately 40 genomic aberrations. Over the past two decades, several efforts to categorize HCC prognostically and therapeutically according to different molecular subclassifications with the intent to guide treatment and identify drug targets have emerged, though, no single consensus has been reached. Recent breakthroughs in drug development have greatly expanded treatment options, but the ideal of uniting each patient's unique HCC with a targeted systemic therapy remains elusive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.